Millennium Management’s Xenon Pharmaceuticals XENE Stock Holding History

Millennium Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65,000	Closed	-$2.61M	–	6528
2025 Q3	$2.61M	Buy	+65,000	New	+$2.29M	﹤0.01%	3802
2023 Q4	–	Sell	-10,000	Closed	-$342K	–	6614
2023 Q3	$342K	Buy	+10,000	New	+$374K	﹤0.01%	4861
2021 Q4	–	Sell	-15,000	Closed	-$229K	–	7456
2021 Q3	$229K	Buy	+15,000	New	+$261K	﹤0.01%	6025

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Millennium Management's XENE Position: Q2 2026 in Review

Millennium Management increased its Xenon Pharmaceuticals (XENE) stake by 87% in Q2 2026, buying an estimated $9.72M and bringing the position to 376,777 shares worth $22.7M. The position accounts for 0.01% of the portfolio, ranked #1515.

Millennium Management first reported a position in XENE in Q4 2016 and has held it in 31 quarters since. The position peaked at $55.6M in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Millennium Management held 376,777 shares of Xenon Pharmaceuticals worth $22.7M as of Q2 2026.
Millennium Management bought 174,992 Xenon Pharmaceuticals shares in Q2 2026, an estimated $9.72M.
Xenon Pharmaceuticals made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1515 holding.
Millennium Management first reported a position in Xenon Pharmaceuticals in Q4 2016 and has held it in 31 quarters since.
Millennium Management's Xenon Pharmaceuticals position peaked at $55.6M in Q3 2025.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.